维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

3篇 您的检索式：作者名="Raul Hernanz"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Atorvastatin Prevents Angiotensin II–Induced Vascular Remodeling and Oxidative Stress显示文摘	Ana M. Briones Natalia Rodríguez-Criado Raquel Hernanz Ana B. García-Redondo Raul R. Rodrigues-Díez María J. Alonso Jesús Egido Marta Ruiz-Ortega Mercedes Salaices	2009	Hypertension2009，，1：	1
	2	Atorvastatin Prevents Angiotensin II–Induced Vascular Remodeling and Oxidative Stress显示文摘	Ana M. Briones Natalia Rodríguez-Criado Raquel Hernanz Ana B. García-Redondo Raul R. Rodrigues-Díez María J. Alonso Jesús Egido Marta Ruiz-Ortega Mercedes Salaices	2009	Hypertension2009，，：	1
	3	Neoadjuvant treatment in non-small cell lung cancer:New perspectives with the incorporation of immunotherapy显示文摘The aim of neoadjuvant treatment in non-small cell lung cancer(NSCLC)is to eliminate micrometastatic disease to facilitate surgical resection.Neoadjuvant chemotherapy(ChT)in localised NSCLC has numerous advantages over other therapeutic modalities and is considered standard treatment in resectable disease.Treatment with immune checkpoint inhibitors(ICI)improves long-term survival in advanced disease and has a better toxicity profile than conventional therapies.These immunotherapy agents(anti-PD1/PD-L1),administered with or without ChT,are currently being evaluated in the preoperative setting,with initial results showing better pathological response rates and more long-term benefits.Importantly,these drugs do not appear to increase the rate of severe adverse effects and/or postoperative complications.However,several questions still need to be resolved,including the identification of predictive biomarkers;comparative studies of immunotherapy alone vs combined treatment with ChT and/or radiotherapy;the optimal duration of treatment;the timing of surgery;the need for adjuvant treatment;appropriate radiologic evaluation and mediastinal staging;and the correlation between pathological response and survival outcomes.Here we review the current evidence for immunotherapy from a multidisciplinary perspective and discuss current and future controversies.	Carlos Aguado Luis Chara Mónica Antonanzas Jose Maria Matilla Gonzalez Unai Jiménez Raul Hernanz Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Counago	2022	World Journal of Clinical Oncology2022，13，5：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费